HOME >> MEDICINE >> NEWS
HIV inserts into human genome using a DNA-associated protein

herited, along with cellular human genes.

Bushman and his team made cells that were depleted of LEDGF and found that integration was less frequent in transcription units and in genes regulated by LEDGF. "This implies that LEDGF is part of the machinery that helps dictate the placement of retroviral integration sites within chromosomes," says Bushman.

Bushman notes that finding that LEDGF is part of the cellular apparatus necessary for HIV replication is important to the field of gene therapy. Controlling where gene-therapy vehicles insert in the human genome could help make the delivery of new therapeutic sequences safer. The new findings about LEDGF suggest that engineered tethering interactions might some day allow control over integration site selection during gene therapy. According to Bushman, this finding is of particular importance in light of recent cases where integration of gene-therapy vectors near cancer genes contributed to the development of leukemia in gene-therapy patients.

"This is first example of a cellular factor that's a clear player in target site selection," says Bushman. "This isn't engineering yet, but it's a key piece of information on the way."


'"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
27-Nov-2005


Page: 1 2

Related medicine news :

1. New research discovers independent brain networks control human walking
2. UD scientists invent novel hydrogels for repairing, regenerating human tissue
3. Report calls for new directions, innovative approaches in testing chemicals for toxicity to humans
4. Stanford researchers track human stem cells transplanted into rat brain
5. Medicalizing the human condition
6. Vaxfectin-formulated measles DNA vaccine elicits long-term protection in nonhuman primates
7. Transplanting human gut bugs into mice helps understanding of metabolic system
8. Tests show healthy humans not harmed by Taser
9. Testing the taser on human subjects -- preliminary physiological measurements
10. Pioneering study maps attention, memory and language links in the human brain
11. Groundbreaking principles on sexual orientation and human rights released

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: HIV inserts into human genome using DNA associated protein

(Date:4/26/2015)... New York, New York (PRWEB) April 26, 2015 ... convened on April 21, 2015 in the U.S. ... of federally-filed testosterone lawsuits ( http://www.testosteronelawsuithub.com/ ) ... pretrial proceedings. According to court documents, matters addressed ... to seek dismissal of claims involving their products ...
(Date:4/26/2015)... (PRWEB) April 26, 2015 Italian public ... deadly legacy of asbestos cement plants and other asbestos-related ... the new research. Click here to read it ... Italy’s Department of Occupational and Environmental Medicine analyzed more ... and found 32 clusters where the asbestos cancer was ...
(Date:4/26/2015)... 26, 2015 Compare-autoinsurance.org has released a new ... quotes . , The easiest way to find low cost ... access to the best offers online, in a simple and ... providers for information about auto insurance prices. All the details ... page. , It is now possible to compare online ...
(Date:4/26/2015)... (PRWEB) April 26, 2015 Indiana Fiber ... provider announces that Brotherhood Mutual Insurance Company has selected ... Manager of Network Infrastructure at Brotherhood Mutual Insurance Company ... the service reliability Brotherhood Mutual needed. We ... and IFN worked with us to ensure we achieved ...
(Date:4/26/2015)... With the FCPX LUT B&W pack from ... can quickly and easily add desaturated color grades to footage. ... formula for modifying an image. The LUT changes every pixel's ... pack comes with 60 black and white CUBE LUT files. ... and white films. With the FCPX LUT B&W Loader ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal Testosterone Treatment Lawsuits Convenes April Case Management Conference 2Health News:Court Overseeing Federal Testosterone Treatment Lawsuits Convenes April Case Management Conference 3Health News:Court Overseeing Federal Testosterone Treatment Lawsuits Convenes April Case Management Conference 4Health News:New Investigation Finds Mesothelioma “Clusters” Around Italian Cement Plants, According to Surviving Mesothelioma 2Health News:Finding Low Cost Auto Insurance - An Online Guide Provides Tips 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 3Health News:Pixel Film Studios, a FCPX Effects Developer, Announced the Release of FCPX LUT B&W 2
(Date:4/23/2015)... , April 24, 2015  AbbVie (NYSE: ... Drug Administration (FDA) has accepted its New Drug Application ... interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir ... treatment of adults with chronic genotype 4 (GT4) hepatitis ... the first all-oral, interferon-free therapy being evaluated by the ...
(Date:4/23/2015)...  ResMed Inc. (NYSE: RMD ) today announced ... for the quarter was $422.5 million, a 6 percent ... (a 13 percent increase on a constant currency basis).  ... percent compared to the quarter ended March 31, 2014.  ... an increase of 2 percent compared to the quarter ...
(Date:4/23/2015)... 2015 /CNW/ - Health Canada is working with the ... the safety information regarding the risk of serious cardiovascular ... products are used at high doses (at or above ... of use. Ibuprofen is a non-steroidal anti-inflammatory ... to reduce inflammation. The majority of ibuprofen products in ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 11ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 12ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 13Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 2Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 3Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 4
Cached News: